http://rdf.ncbi.nlm.nih.gov/pubchem/patent/ES-2433577-T3
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_5fece74aa8c0cb73d997c194165159cc |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-58 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-65 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-6883 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-48 |
| filingDate | 2009-09-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2013-12-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c55396e5c18cd16d30c68b0b679873b8 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_04fa615bb376da751e2dbde0db87e1dc http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e757d92d8d417dbc993a6f5a4ff7ee9c http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0713feb0e1b1bdc3060f54a25bba6302 |
| publicationDate | 2013-12-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | ES-2433577-T3 |
| titleOfInvention | Polymeric composition with synergistic effect in the treatment of tumor diseases |
| abstract | Pharmaceutical composition that has an important cytotoxic anti-tumor activity and a simultaneous anti-tumor-stimulating effect, with the active substance doxorubicin, in which the composition comprises two components, in which: a) the first component that forms the composition is a copolymer of N- (2 -hydroxypropyl) methacrylamide (HPMA) called PK1, in which the doxorubicin is bound to the polymeric carrier through the enzymatically cleavable GlyPheLeuGly oligopeptide sequence, in which the polymer chain comprises 50 to 1,000 monomer units comprising 80 to 99% molar units of N- (2-hydroxypropyl) methacrylamide (HPMA), 1 to 5% molar of the oligopeptide (GlyPheLeuGly) terminated methacrylate with an amide bond of joined side oxorubicin, 0 to 10% molar of the finished oligopeptide (GlyPheLeuGly) with a 0 to 10% molar carboxy group of the oligopeptide (GlyPheLeuGly) methacrylated terminated with the 2-hydr group Oxypropylamide and, optionally, 0.5 to 10% molar units of a methacrylated oligopeptide (GlyPheLeuGly) terminated with a molecule of a non-specific human antibody, such as Hulg, Endobulin, Intraglobin, or monoclonal antibody, such as Erbitux , or Herceptin; b) the second component is an HPMA copolymer called H, in which the doxorubicin is bound to a polymeric carrier through a spacer comprising a hydrolytically labile hydrazitically sensitive alpH bond, comprising from 30 to 3,500 monomer units connected in a polymer chain linear or branched formed from 60 to 98.5% of HPMA units and also comprises 1 to 20% of hydrazonasmetacriloiladas units of a-amino acids, e-amino acids, aromatic amino acids or oligopeptides terminated with a doxorubicin molecule, from 0.5 to 15% of hydrazide units of methacrylic amino acids, e-amino acids, aromatic amino acids or oligopeptides or their sodium salts, and, optionally, 0.5 to 5% of methacrylated amino acid units, e-amino acids , aromatic amino acids uolipeptide terminated with a molecule of an immunoglobulin or a specific monoclonal antibody. |
| priorityDate | 2008-10-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 40.